title: American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
authors.affiliation: Thomson Current Drugs, London, UK. rebecca.erlich@current-drugs.com
authors.forename: Rebecca
authors.initials: R
authors.lastname: Erlich
authors.forename: Anna
authors.initials: A
authors.lastname: Durrance
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects; D010793:Phthalazines / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009842:Oligopeptides; D010793:Phthalazines; D011725:Pyridines; D000068258:Bevacizumab; C404768:vatalanib